Organovo Holdings (ONVO) vs. Jaguar Animal Health (JAGX) Head to Head Analysis

Organovo Holdings (NASDAQ: ONVO) and Jaguar Animal Health (NASDAQ:JAGX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Earnings & Valuation

This table compares Organovo Holdings and Jaguar Animal Health’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Organovo Holdings $4.23 million 38.93 -$38.44 million ($0.38) -4.05
Jaguar Animal Health $140,000.00 87.04 -$14.73 million ($1.03) -0.17

Jaguar Animal Health has higher revenue, but lower earnings than Organovo Holdings. Organovo Holdings is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Organovo Holdings and Jaguar Animal Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Organovo Holdings -923.89% -62.67% -57.68%
Jaguar Animal Health -757.17% N/A -301.91%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Organovo Holdings and Jaguar Animal Health, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organovo Holdings 0 2 3 0 2.60
Jaguar Animal Health 0 0 2 0 3.00

Organovo Holdings currently has a consensus target price of $6.94, suggesting a potential upside of 350.49%. Jaguar Animal Health has a consensus target price of $2.00, suggesting a potential upside of 1,011.11%. Given Jaguar Animal Health’s stronger consensus rating and higher possible upside, analysts clearly believe Jaguar Animal Health is more favorable than Organovo Holdings.

Volatility and Risk

Organovo Holdings has a beta of 3.13, indicating that its share price is 213% more volatile than the S&P 500. Comparatively, Jaguar Animal Health has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.

Institutional and Insider Ownership

24.2% of Organovo Holdings shares are held by institutional investors. Comparatively, 7.1% of Jaguar Animal Health shares are held by institutional investors. 10.2% of Organovo Holdings shares are held by company insiders. Comparatively, 19.5% of Jaguar Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Jaguar Animal Health beats Organovo Holdings on 7 of the 13 factors compared between the two stocks.

About Organovo Holdings

Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.

About Jaguar Animal Health

Jaguar Health, Inc., formerly Jaguar Animal Health, Inc., is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. Its other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.

Receive News & Ratings for Organovo Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply